Figure 3.

NK cell activation correlates with elotuzumab concentration. A) CD56^dim NK cell activation from a representative healthy donor was measured as percentage of CD69⁺ cells after overnight incubation without (left) or with 1ug/ml Elo (right), as indicated in the box gate. B) Percentage of CD56^dim NK cells in PBMCs from 3 healthy donors expressing CD69 after overnight exposure to indicated concentrations of Elo alone. C) Viability of CD56^dim NK cells as the percentage of PI-negative CD56^dim NK cells for each condition.